✦ LIBER ✦

A phase II study of cisplatin therapy in recurrent childhood brain tumors

✍ Scribed by Salvatore J. Bertolone; Edward S. Baum; William Krivit; G. Denman Hammond

Book ID: 104642773
Publisher: Springer US
Year: 1989
Tongue: English
Weight: 341 KB
Volume: 7
Category: Article
ISSN: 0167-594X
DOI: 10.1007/bf00149372

No coin nor oath required. For personal study only.

✦ Synopsis

Thirty-six children with brain tumors were treated with surgery, radiation and/or adjuvant chemotherapy. After tumor recurrence, cisplatin (60 mg/m2/day IVx 2) was given every three to four weeks. CT scans were used to measure drug response prior to the first, third and fifth courses. Complete and partial responses were demonstrated in nine of 31 evaluable patients. Dose limiting toxicities were renal and auditory. Seven patients developed the syndrome of inappropriate antidiuretic horr, one secretion. This study confirms that cisplatin is active in a spectrum of brain tumors.

📜 SIMILAR VOLUMES

Cisplatin in recurrent pediatric brain t

Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study

✍ Charles L. Sexauer; Atiya Khan; Peter C. Burger; Jeffrey P. Krischer; Jan Van Ey 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m\*/day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) sca

Carboplatin in childhood brain tumors: A

Carboplatin in childhood brain tumors: A children's cancer study group phase II trial

✍ Paul S. Gaynon; Lawrence J. Ettinger; Edward S. Baum; Stuart E. Siegel; Mark D. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 3 views

Phase II study of daily oral etoposide i

Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors

✍ Needle, Michael N.; Molloy, Patricia T.; Geyer, J. Russell; Herman-Liu, Alisa; B 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 2 views

Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of or

A phase II randomized study comparing se

A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors: A southwest oncology group study

✍ Joanne E. Mortimer; John Crowley; Harmon Eyre; Paul Weiden; James Eltringham; W. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB

The Southwest Oncology Group conducted a trial of intraarterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered concomitant with or before radiation therapy. Because of technical difficulties cannulating the artery, 27 of 33 eligible patients were able to receive the cisplati

Phase II study of cisplatin in recurrent

Phase II study of cisplatin in recurrent astrocytomas in adults: A southwest oncology group study

✍ David J. Stewart; Robert M. O'Bryan; Muhyi Al-Sarraf; John J. Costanzi; Noboru O 📂 Article 📅 1983 🏛 Springer US 🌐 English ⚖ 215 KB

Thirty-one evaluable adults with recurrent astrocytomas were treated with Cisplatin 35 mg/m 2 I.V. daily for three days every 3 4 weeks. All patients had previously been irradiated and most had previously received chemotherapy. Approximately half had poor performance status. Two patients experienced

Phase II study of pirarubicin combined w

Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer

✍ A. du Bois; H. G. Meerpohl; H. Madjar; D. Spinner; P. Dall; J. Pfisterer; T. Bau 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 693 KB